TaiMed Biologics, Inc., a biotechnology company, engages in the discovery, development, and delivery of medicines primarily for HIV/AIDS in Taiwan. Its product pipeline includes TMB-355, a phase IIb viral-entry inhibitor that blocks monoclonal antibody for the treatment of HIV/AIDS; TMB-607, a novel HIV-1 protease inhibitor; and TMB-571, a small molecule inhibitor of influenza virus neuraminidase. The company also engages in a cooperative program for 2nd generation TMB-355, and HIV integrase inhibitor program. TaiMed Biologics, Inc. was founded in 2007 and is based in Taipei, Taiwan.
taimed biologics inc
(4147:GreTai Securities Market)
No. 3, Yuan-Qu Street
Phone: 886 2 2655 8031
Fax: 886 2 2655 8205www.taimedbiologics.com.tw
|No competitor information is available for 4147.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact TAIMED BIOLOGICS INC, please visit www.taimedbiologics.com.tw. Company data is provided by Capital IQ. Please use this form to report any data issues.